Quarterly beat and restructuring set the stage for Charles River Laboratories stock
Charles River Laboratories International (CRL) recently beat quarterly expectations and introduced a new US$1b share repurchase authorization, while simultaneously restructuring through divestitures, site closures, and workforce reductions.
See our latest analysis for Charles River Laboratories International.
Despite the recent beat, Charles River Laboratories International's 1 day share price return of 1.83% comes after a 7 day share price return of 10.89% and a year to date share price return of 23.20%. The 5 year total shareholder return of 45.77% indicates that longer term investors have faced a much weaker outcome. This suggests that recent restructuring news and new collaborations in cell and gene therapies are reshaping how the market views both its prospects and its risks.
If this kind of volatility has you looking beyond a single name, it could be a good moment to see what stands out in our 33 healthcare AI stocks as another way to research healthcare related growth stories.
So with Charles River Laboratories trading at US$155.46, sitting on a 23.20% year to date gain and a 45.77% 5 year total return, and with a fresh US$1b buyback in place, is there still an opportunity here or is future growth already priced in?
Most Popular Narrative: 50.4% Undervalued
Compared to Charles River Laboratories International's last close at $155.46, the most followed narrative on Simply Wall St points to a fair value of $313.61, implying a large gap between market price and that estimate.
The acquisition of K.F. (Cambodia) by Charles River Laboratories in January 2026 is more than just another corporate transaction. It reflects a deeper reality within the drug development ecosystem. The availability of non-human primates has become one of the hidden bottlenecks in modern biomedical research. As long as biological, regulatory, and geopolitical constraints remain in place, access to NHP supply will continue to shape the economics and operational capacity of the global preclinical CRO industry.
According to AnimalDoctorKwon, that $313.61 fair value leans heavily on a specific growth path for revenue, a step change in profitability and a future earnings multiple that assumes the market will treat Charles River more like a high quality compounder rather than a low growth lab service. Curious which of those levers has to do most of the heavy lifting for the valuation to hold up and how sensitive the outcome is if one of them falls short.
Result: Fair Value of $313.61 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on continued access to non human primates and assumes that current regulatory, ethical and geopolitical pressures around animal testing do not tighten meaningfully.
Find out about the key risks to this Charles River Laboratories International narrative.
Another View: Cash Flows Paint a Tougher Picture
The user narrative leans on a $313.61 fair value and calls Charles River Laboratories undervalued, but our DCF model comes out far more cautious. On that framework, CRL at $155.46 sits above an estimated future cash flow value of $138.35, which screens as overvalued instead.
If one model points to a large upside and another suggests the cash flows do not quite support the current $155.46 price, which set of assumptions do you feel more comfortable leaning on when real money is involved?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
The split between the bullish narrative and the more cautious cash flow view makes the story interesting, so take a moment to look through the numbers yourself and decide where you stand. Then see how that compares with the 2 key rewards and 2 important warning signs that other investors are focusing on.
Looking for more investment ideas?
If CRL's mix of moving parts has your attention, do not stop here. Broaden your watchlist with other ideas that match your own risk and return preferences.
- Target quality at a discount by scanning our list of 48 high quality undervalued stocks that pair solid fundamentals with prices that sit below our fair value estimates.
- Strengthen the income side of your portfolio by reviewing 14 dividend fortresses, focusing on companies offering 5%+ yields with an emphasis on resilience.
- Favor resilience over drama by checking 68 resilient stocks with low risk scores, highlighting companies with lower risk scores that can help balance out more volatile positions.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com